Sugi Predict

Sugi Predict / Compounds / SCHEMBL1621691

SCHEMBL1621691

SCHEMBL1621691

CC(C)CN1CCN(CC(C)C)CC1

nearest known ligand 0.61

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 4/20 0.61
▸ CYP2D6 P10635 3/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ SLC2A1 P11166 1/20 0.37
▸ COMT P21964 1/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ HRH3 Q9Y5N1 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2001262 1.00 — —
SCHEMBL20438377 1.00 PIK3CD (0.61) PIK3CDCYP2D6SMN1; SMN2SLC2A1COMT
SCHEMBL24209746 1.00 PIK3CD (0.61) PIK3CDCYP2D6SMN1; SMN2SLC2A1COMT
Hydrochloric Acid SCHEMBL5183545 0.97 — —
SCHEMBL22300882 0.88 PIK3CD (0.52) PIK3CDCYP2D6SMN1; SMN2HRH3L3MBTL1
SCHEMBL101927 0.88 PIK3CD (0.52) PIK3CDCYP2D6SMN1; SMN2SLC2A1L3MBTL1
SCHEMBL14328666 0.88 PIK3CD (0.52) PIK3CDCYP2D6SMN1; SMN2HRH3L3MBTL1
SCHEMBL22013047 0.88 PIK3CD (0.52) PIK3CDCYP2D6SMN1; SMN2HRH3L3MBTL1
SCHEMBL7907337 0.88 PIK3CD (0.52) PIK3CDCYP2D6SMN1; SMN2HRH3L3MBTL1
SCHEMBL25443765 0.87 PIK3CD (0.50) PIK3CDCYP2D6SMN1; SMN2SLC2A1COMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024318-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-20240024318-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-11858925-B2 GAS41 inhibitors and methods of use thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-01-02 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
WO-2023205807-A2 PROTEOLYSIS TARGETING CHIMERAS FOR HUMAN PREGNANE X RECEPTOR AND FOR DEGRADATION OF GSPT1 ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2023-10-26 — — WO disclosed
US-20230321253-A1 BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-10-12 — — US disclosed
EP-1159315-A1 PROCESS FOR PRODUCING POLYETHYLENE EASTMAN CHEMICAL COMPANY (US) 2001-12-05 — — EP disclosed
US-20010031841-A1 Procatalysts, catalyst systems, and use in olefin polymerization WESTLAKE LONGVIEW CORPORATION 2001-10-18 — — US disclosed
US-20010029286-A1 Procatalysts, catalyst systems, and use in OLEFIN polymerization EASTMAN CHEMICAL COMPANY, A CORP. OF DELAWARE 2001-10-11 — — US disclosed
US-20010025005-A1 Procatalysts, catalyst systems, and use in olefin polymerization EASTMAN CHEMICAL COMPANY, A CORPORATION OF DELAWARE 2001-09-27 — — US disclosed
US-6271321-B1 CATALYTIC POLYMERIZATION OR COPOLYMERIZATION OF ETHYLENE AND OLEFIN MONOMERS EASTMAN CHEMICAL COMPANY 2001-08-07 — — US disclosed
WO-2000075203-A1 PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS EASTMAN CHEMICAL COMPANY (US) 2000-12-14 — — WO disclosed
WO-2000075202-A1 PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS EASTMAN CHEMICAL COMPANY (US) 2000-12-14 — — WO disclosed
WO-2000052068-A1 PROCESS FOR PRODUCING POLYETHYLENE EASTMAN CHEMICAL COMPANY (US) 2000-09-08 — — WO disclosed
EP-0309844-B1 PROCESS FOR THE PREPARATION OF CHLOROTHIOL FORMIATES BASF Aktiengesellschaft (DE) 1991-12-04 — — EP disclosed
EP-0309844-A1 Process for the preparation of chlorothiol formiates BASF Aktiengesellschaft (DE) 1989-04-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, TP53, MDM4 PIK3CD 1248/4885CYP2D6 1170/4885SMN1; SMN2 3149/4885
US-20240024318-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCA2, SMARCC2 PIK3CD 1678/4885CYP2D6 2910/4885SMN1; SMN2 716/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PIK3CD 321/4885CYP2D6 3599/4885SMN1; SMN2 2647/4885
US-11858925-B2 GAS41 inhibitors and methods of use thereof GAS6, HIF1AN, TMEM41B PIK3CD 4323/4885CYP2D6 4665/4885SMN1; SMN2 4566/4885
US-20230321253-A1 BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF KRAS, MDM2, NRAS PIK3CD 577/4885CYP2D6 3961/4885SMN1; SMN2 2524/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PIK3CD 321/4885CYP2D6 3599/4885SMN1; SMN2 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.